MEMohamed Sabry El-Ghonemy

Mohamed Sabry El-Ghonemy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mohamed Sabry El-Ghonemy has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical Impact of CD25/CD123 Coexpression in Adult B-Cell Acute Lymphoblastic Leukemia Patients

    by Salah Aref, Mohamed El Agdar, Nada Khaled, Lamyaa Ibrahim, Mohamed S. El-Ghonemy

    This study aimed to determine the clinical impact of CD25+/CD123+ coexpression in adult B-cell acute lymphoblastic leukemia (B-ALL) cases. One hundred and twenty newly diagnosed B-ALL patients (60 years old) were included in this study. CD123 and CD25 expression on leukemic blast cells were assessed using flow cytometry. CD25+/CD123+ coexpression was detected in 40/120 B-ALL patients (33.3). All B-ALL patients showed CD25+/CD123+ coexpression had lower induction of remission response and shorter overall survival as compared to B-ALL cases lacking coexpression. In conclusion, CD25+/CD123+ positive coexpression is a reliable flow cytometry marker for prediction of the outcome of adult B-ALL patients and could be used as a novel parameter for risk stratification of adult B-ALL cases.


  • Open Access

    Thrombophilic Risk of Factor V Leiden, Prothrombin G20210A, MTHFR, and Calreticulin Mutations in Essential Thrombocythemia Egyptian Patients

    by Mohamed S. El-Ghonemy, Solafa El Sharawy, Maryan Waheeb Fahmi, Shaimaa El-Ashwah, May Denewer, Ma El-Baiomy

    Objectives. Essential thrombocythemia (ET) is one of the myeloproliferative neoplasms characterized by a sustained elevation of platelet numbers with a tendency for thrombosis and hemorrhage. The aim of this work is to establish the relation between calreticulin, factor V Leiden, prothrombin G20210A, and MTHFR mutations in ET patients and the thrombotic risk of these patients. Methods. This study was carried out on 120 ET patients and 40 apparently healthy individuals as a control group. Results. There were increases in WBCs, PLT counts, PT, fibrinogen concentration factor V Leiden, and MTHFR mutation in ET patients as compared to the control group (P<0.05). Also, there were increases in WBCs, PLT counts, and hematocrit value in thrombosed ET patients as compared to the nonthrombosed ones (P<0.05). On the contrary, there was no significantly statistical difference in ET patients with JAK2 V617F positive mutation versus the JAK2 negative group (P>0.05) and in patients with cardiovascular risk factors versus patients with noncardiovascular risk factors (P>0.05). ET patients with factor V Leiden, prothrombin gene, and CALR mutations were more prone to thrombosis (odds ratio 5.6, 5.7 and 4.7, respectively). On the contrary, JAk2V 617F and MTHFR mutations have no effect on the thrombotic state of those patients. Conclusion. There is a significant increase risk of thrombosis in ET patients with CALR mutation, thrombophilic mutations, as well as factor V Leiden and prothrombin gene mutation with a risk of developing leukemic transformation.


  • Open Access

    Prognostic Impact of Lymphoid Enhancer Factor 1 Expression and Serum Galectin.3 in Egyptian AML Patients

    by M. A. ElBaiomy, S. Aref, M. El Zaafarany, Sara Atwa, Tamer Akl, Wafaa El-Beshbishi, Shaimaa El-Ashwah, L. Ibrahim, M. El-Ghonemy

    Background. Deregulation of the Wnt signaling pathway had a role in haematological malignancies. Previous studies reported that lymphoid enhancer factor 1 (LEF1) expression and serum Galectin-3 level could affect clinical parameters and outcome in acute myeloid leukemia patients, but as far as we know, no study has addressed their combined effect on AML patients.Aim. We studied the expression of LEF1 by real-time qPCR and measured serum level of Gal.3 by ELISA technique in peripheral blood of 69 AML patients and correlated it with different clinicopathological criteria of patients, response, PFS and OS.Results. We found high expression (LEF1high) was associated with better OS (p=0.02) and EFS (p=0.019) compared to LEF1low, low serum Gal.3 level had better OS (p=0.014) and EFS (p=0.02) compared to high serum Gal.3 level. LEF1highless likely to carry a FLT3-ITD (p=0.047) compared to LEF1lowpatient, also LEF1highcharacterized by favorable risk (p=0.02) than LEF1lowpatients. While patients with higher Gal-3 levels characterized by poor risk (p=0.02) than lower Gal.3 lels, also more likely to carry a FLT3-ITD with borderline significance (p=0.054). Combined LEF1high/Gal.3 low patients had lower baseline blast percentages (p=0.02), favorable risk (p=0.01), less likely to carry FLT3-ITD (p=0.02), higher CR rate (p=0.055), shorter time to CR (0.001) than other groups. Among high Gal.3 level group, LEF1highexpression improved OS and EFS (20 and 15 months respectively) vs LEF1lowexpression (13 and 8 months respectively).Conclusion. We conclude that high LEF1 expression was a favorable prognostic marker which can define AML patient risk and outcome independent from assessing the serum galectin.3 level.


  • Open Access

    Osteopontin level and promoter polymorphism is associated with aggressiveness in breast cancer

    by M.A. Elbaiomy, M.S. El-Ghonemy, R. Elhelaly, R. Elzehery

    Background: Osteopontin (OSP) is a metastasis-related gene associated with progression cancers. We assigned osteopontin as potential contributors in breast cancer.


  • Prognostic relevance of CD69 expression in B cell chronic lymphocytic leukemia

    by Salah Aref, Nadia El Menshawy, Mohamed Sabry El-Ghonemy, Ghada El-Said, Mohamed Ali El-Baiomy